Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02627742 · ClinicalTrials.gov registry record · NA
Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications
A NA study of Atelectasis and Pulmonary Complications, sponsored by Hill-Rom.
- Completed
- Registry status
- NA
- Development phase
- 419
- Enrollment target
- 3
- Study locations
NCT02627742 is a NA study of Atelectasis and Pulmonary Complications that has completed, run by Hill-Rom. The registered enrollment target is 419 participants, above the 97-participant average among 3 other Atelectasis trials with a reported enrollment target (332% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT02627742, a NA study of Atelectasis and Pulmonary Complications, has completed, sponsored by Hill-Rom.
- COMPLETED
- Registry status
- NA
- Development phase
- 419 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determine if a therapy regimen including treatment with The MetaNeb® System had a positive impact on the rate of pulmonary complications related to atelectasis and/or secretion retention that occur in high risk post-operative patients. This is a non-randomized facility (or hospital) level pre-post intervention study.
Conditions Studied
Interventions
- DEVICE MetaNeb® System
Study Locations (3)
Massachusetts
- Lahey Hospital and Medical Center - Burlington
North Carolina
- Carolinas Medical Center - Charlotte
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02627742
The ClinicalTrials.gov registry entry for NCT02627742 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 97-participant average among 3 other Atelectasis trials with a reported enrollment target (332% higher). The listed sponsor is Hill-Rom, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atelectasis appearing as the primary indexed condition, and to 1 intervention - of which MetaNeb® System is the first listed.
NCT02627742 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02627742 about?
NCT02627742 is a clinical study titled "Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications". To determine if a therapy regimen including treatment with The MetaNeb® System had a positive impact on the rate of pulmonary complications related to atelectasis and/or secretion retention that occur in high risk post-operative patients. This is a non-randomized facility (or hospital) level pre-pos...
What is the current status of trial NCT02627742?
This trial is currently completed. It is a NA study. The enrollment target is 419 participants. The study started on 2016-03. Estimated completion is 2017-08.
What conditions does trial NCT02627742 study?
This clinical trial studies the following conditions: Atelectasis, Pulmonary Complications.
What interventions are being tested in trial NCT02627742?
The interventions under investigation include: MetaNeb® System (DEVICE).
Who is sponsoring clinical trial NCT02627742?
This trial is sponsored by Hill-Rom, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02627742 being conducted?
This trial has 3 study locations across Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atelectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.